#Vaccines And Vaccination Market

[tip-research24]

Vaccines And Vaccination Market Future Competitive Landscape, Trends, Opportunity and Forecast to 2030

Investors are expected to receive business-oriented market insights from The Insight Partners "Overview of Vaccines And Vaccination Market Share, Size, and 2030" | market study. This study incorporates forecasts for the future market in addition to operational variables. This research addresses a variety of possibilities accessible for Vaccines And Vaccination market participants in addition to drivers and obstacles. Valid facts included in this research have been framed using both primary and secondary research approaches.

Vaccines And Vaccination Market research delves deeply into many categories to provide a thorough perspective for both seasoned players and recent arrivals. Companies may guarantee they have a competitive edge by using this market research to have a better perspective and knowledge of the target audience. Before making significant investments, businesses must have a firm understanding of the market. It makes financial sense to allocate a modest portion of your company's expenditure to reliable market research.

Firms must take an open-minded attitude in light of the competitive landscape discussed in this research. Companies may utilize the objective insights provided by this market research to identify their strengths and limitations. Companies that can capitalize on the fresh ideas gained from competition analysis will have an edge in moving forward.

A market research report, which contains proof of market research and provides the best opportunity for businesses to fulfill their objectives, might serve as the cornerstone of your business strategy.

Key objectives of this research are:

Global Vaccines And Vaccination Market Insights- Market Share, Market Size, and CAGR

To Examine Drivers, Challenges, and Opportunities in Vaccines And Vaccination Market

To offer competitive strategic insights that help businesses ace the game

To offer an actionable market recommendation

To brief on the impact of COVID-19 and present an account of strategic responses businesses can plan.

To analyze the Vaccines And Vaccination market benchmarks.

COVID-19 Impact Analysis

Halting the operations temporarily, an epidemic of COVID-19 influenced on revenues of key Vaccines And Vaccination market players. This section presents details on the range of responses businesses have to pandemic impacts and assists companies in developing post-pandemic strategies. Moving further, this chapter offers insights into supply-demand parameters for businesses to rejoin the market.

Key companies in this Vaccines And Vaccination market are- Serum Institute of India Pvt. Ltd., Pfizer, Johnson & Johnson, AstraZenecea plc, GlaxoSmithKline plc, Sanofi Aventis, Merck & Co., Inc., Emergent BioSolutions Inc., CSL Limited, Novavax, Inc..

To Summarize the Offerings-

Market Forecast- Coverage- Market Size, Share, and CAGR | Forecast by 2030

Market Scope– Aim of the research, A glance at key chapters

Market Dynamics- Drivers, Challenges, Regional Trends, and Market Opportunities

Market Segmentation – Product, Application, End-use Industries, and Regional Growth Prospects.

Market Players – Key Market Players and Strategies

Recent Developments and Innovation in Vaccines And Vaccination Market

Covid-19 Analysis- Industry Landscape During and Post-Pandemic.

Regional Framework- Key Regional Markets, Growth Projections

Market Segmentation Based on Technology this market is categorized further into- :

Recombinant and Conjugate Vaccines

Live Attenuated Vaccines

Inactivated Vaccines

Toxoid Vaccines

Others

Based on Indication this market is categorized further into- :

Pneumococcal Disease

Influenza

Human Papilloma Virus

Meningococcal Disease

Rotavirus

Varicella

Diphtheria

Polio

Hepatitis

Other Indications

Based on End User this market is categorized further into- :

Pediatric

Adults

Travelers

Key regions Vaccines And Vaccination Market Research Report:

North America (U.S., Canada, Mexico)

Europe (U.K., France, Germany, Spain, Italy, Central & Eastern Europe, CIS)

Asia Pacific (China, Japan, South Korea, ASEAN, India, Rest of Asia Pacific)

Latin America (Brazil, Rest of Latin America)

The Middle East and Africa (Turkey, GCC, Rest of the Middle East and Africa)

Rest of the World

About Us: The Insight Partners is a one-stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Devices, Technology, Media and Telecommunications, Chemicals and Materials.

[dreaminginthedeepsouth]

deAdder

* * * *

Jim Wright

Trump has nominated Robert F. Kennedy Jr., a conspiracy nut and rabid anti-vaxxer, to lead the Department of Health and Human Services.

RFK Jr has a long, long history of insane, counterfactual, completely wrong, and at best misleading claims regarding vaccines. I don't thinks he's every said a single word about vaccines that was correct. There isn't an unhinged vaccine conspiracy theory Kennedy doesn't love and believe whole hog.

He's lost literally hundreds of lawsuits over vaccines.

But NOW he's going be in charge of vaccination for the entire country.

We're literally going to put the biggest nut in the booby hatch in charge, and we're going to lock up all the doctors.

Guess Liberals should have shown up, eh? Then again, anti-vax conspiracy theories have long been a popular bugaboo on the far left, which is where Kennedy himself came from, so maybe the Left is getting exactly what it wanted after all.

Be that as it may, or may not be, Kennedy has said the government won't out and out outlaw vaccines, but will just make it so they aren't mandated.

Vaccines won't be mandatory and no one from schools to employers to the military will be able to make them so.

(You probably don't want to spend too much time imagining the massive vulnerability any unvaccinated military will face in a battlespace where disposable $100 drones can easily spray biological agents over wide areas...)

Anyway, you'll still be able to get your family vaccinated.

But your insurance won't cover it.

Oh, you didn't think about THAT, did you?

Yeah, if vaccines aren't mandatory, AND the government agency tasked with certifying their effectiveness is run by a bunch of drooling lunatics who think Froot Loops make kids gay or something, well, then there isn't any way in hell that your insurance company is going to pay for them. Especially when they repeal the ACA slash Obamacare.

In practical terms what this means is that ONLY the rich will be fully vaccinated.

And the poor will be ravaged by disease.

Oh, and it's not just going to be measles, mumps, polio, whooping cough, flu, COVID, etc. No no. It'll be the classics like cholera and typhus too, because Trump, RFK, and the new Department of Government Efficiency run by Vivek Ramaswamy and Elon Musk, are ALSO going to get rid of health inspectors, you know, the people who make sure your food isn't contaminated by rat flees or your drinking water doesn't have human shit in it.

Don't worry, I'm sure the Free Market will sort it out soon enough, and at a profit too.

When Trump said make America like the 1700s again, Buddy, he wasn't kidding

[bisexualalienss]

get all your vaccines updated now. that’s all all going to say. including your covid vaccines

[nerdgirlnarrates]

Of the many things to be scared about, I am particularly fearful of what RFK Jr having a prominent role in public health would mean

[healthcareporium]

Immunomodulators' Power: Widening Applications and Medical Impact

Immunomodulators have emerged as crucial components in the field of medicine, gaining increasing attention for their ability to regulate and modify the immune system’s responses. These agents play a pivotal role in treating a diverse range of conditions, from autoimmune diseases and cancer to infectious diseases and organ transplants. By modulating immune responses, immunomodulators offer…

[industryexperts]

(via Biopharmaceuticals Market Size, Outlook 2024-2030)

[yimarcgroup]

mRNA Vaccines and Therapeutics Market Size, Report 2032

The mRNA vaccines and therapeutics market size reached USD 57.7 Billion in 2024 to reach USD 72.7 Billion by 2033 at a CAGR of 2.53% during 2025-2033.

[anujmrfr]

Human Rotavirus Vaccine Market Size, Growth Outlook 2035

Human Rotavirus Vaccine Market Size was valued at USD 10.41 Billion in 2023. The Global Human Rotavirus Vaccine industry is projected to grow from USD 11.30 Billion in 2024 to USD 19.97 Billion by 2032

Summary

The global human rotavirus vaccine market is experiencing strong growth due to rising awareness about rotavirus-related diseases, increasing immunization programs, and strong government initiatives to control diarrheal diseases in children. Rotavirus is a leading cause of severe diarrhoea in infants and young children, and vaccination is the most effective way to prevent the disease. The market is driven by increasing birth rates, improving healthcare infrastructure in developing nations, and the inclusion of rotavirus vaccines in national immunization programs. However, vaccine shortages, high costs, and concerns over side effects pose challenges to market expansion.

Market Overview

Rotavirus vaccines help prevent severe gastroenteritis caused by rotavirus infections, significantly reducing hospitalizations and fatalities in children. The World Health Organization (WHO) strongly recommends universal rotavirus vaccination, and many countries have integrated rotavirus immunization into their national vaccination schedules. The introduction of new-generation vaccines with improved efficacy and reduced cold chain dependency is further boosting market growth.

Market Size and Growth Analysis

Human Rotavirus Vaccine Market Size was valued at USD 10.41 Billion in 2023. The Global Human Rotavirus Vaccine industry is projected to grow from USD 11.30 Billion in 2024 to USD 19.97 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 6.54% during the forecast period (2024 - 2032).

Market Dynamics

Growth Drivers

Increasing Global Immunization Coverage: Many countries are expanding their immunization programs to include rotavirus vaccines, improving accessibility.

High Burden of Rotavirus-Related Morbidity and Mortality: Rotavirus is responsible for over 200,000 child deaths annually, prompting urgent vaccination efforts.

Government & Non-Government Support for Vaccination Programs: Organizations such as WHO, UNICEF, and Gavi, the Vaccine Alliance are actively funding rotavirus immunization programs.

Advancements in Vaccine Formulation: The development of thermostable and orally-administered vaccines is improving ease of use and distribution, especially in remote areas.

Challenges and Restraints

High Vaccine Costs in Low-Income Countries: The cost of vaccines remains a barrier in regions with limited healthcare funding.

Cold Chain Requirements for Storage & Distribution: Some vaccines require strict temperature control, making logistics challenging in developing nations.

Concerns Over Vaccine-Related Side Effects: Although rare, reports of intussusception (a type of bowel obstruction) associated with some vaccines raise concerns among parents and healthcare providers.

Regional Analysis

North America

Largest market, driven by high immunization rates, strong government support, and advanced healthcare infrastructure.

The United States dominates the market due to CDC recommendations and private sector vaccination programs.

Europe

Second-largest market, benefiting from universal vaccination policies, strong research funding, and advanced vaccine distribution networks.

Germany, the UK, and France lead in vaccine adoption.

Asia-Pacific

Fastest-growing region, fueled by rising birth rates, government-backed immunization programs, and increasing vaccine accessibility.

India, China, and Southeast Asia are key markets due to large pediatric populations and increasing healthcare investments.

Latin America, Middle East & Africa

Emerging markets, experiencing gradual vaccine adoption with strong WHO and UNICEF support for immunization programs.

Brazil, South Africa, and Mexico are showing increased vaccine coverage due to government-led mass immunization initiatives.

Market Segmentation

By Vaccine Type:

Monovalent Vaccines (Single Strain)

Pentavalent Vaccines (Multiple Strains)

By Route of Administration:

Oral Vaccines (most commonly used)

Injectable Vaccines (under development for improved efficacy)

By End-User:

Hospitals & Pediatric Clinics

Government & Non-Governmental Immunization Programs

Retail Pharmacies

Key Market Players

The human rotavirus vaccine market share is rising because of the performance of the following leading companies

Bharat Biotech

Serum Institute of India Pvt. Ltd.

GlaxoSmithKline plc.

Merck & Co., Inc.

BIOVIRx Inc.

Sanofi

Recent Developments

Introduction of Next-Generation Thermostable Vaccines: New formulations are being developed to eliminate cold chain dependency for easier transportation.

Expansion of Government-Funded Immunization Programs: Several low- and middle-income countries are increasing vaccine funding and accessibility.

Growing Investments in Oral Vaccine Research: Oral rotavirus vaccines are being enhanced for better efficacy and ease of administration.

Future Outlook and Opportunities

The global human rotavirus vaccine market is expected to grow steadily due to increasing vaccine adoption, ongoing research in improved vaccine formulations, and expanding government-backed immunization efforts. Future developments in thermostable, needle-free, and cost-effective vaccines will further enhance accessibility and coverage worldwide.

For more information visit to @marketresearchfuture

[healthcaremarketanalysis]

Vaccine Storage Equipment Market: Trends, Opportunities, and Growth Drivers

The vaccine storage equipment market is experiencing robust growth, driven by advancements in healthcare infrastructure, the increasing global demand for vaccines, and rising concerns about maintaining vaccine efficacy through proper storage. Vaccines are highly sensitive biological substances that require specific temperature conditions to remain effective. The equipment used to store vaccines, including refrigerators, freezers, and monitoring devices, plays a crucial role in ensuring the success of immunization programs worldwide.

In this blog, we will explore the vaccine storage equipment market, its current trends, growth opportunities, key challenges, and the factors influencing its expansion.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=52873073

Market Overview

The vaccine storage equipment market refers to the segment of the healthcare industry that manufactures and distributes equipment designed for storing vaccines at controlled temperatures. Proper vaccine storage is critical to preserving the potency of vaccines, especially those sensitive to temperature fluctuations like mRNA vaccines.

In recent years, the market has witnessed remarkable growth due to:

Increased Vaccination Campaigns: Governments and organizations are undertaking extensive vaccination drives, including COVID-19 vaccination efforts.

Rising Investments in Cold Chain Infrastructure: Many regions, particularly in developing countries, are upgrading their cold chain systems to improve vaccine accessibility.

Technological Advancements: Innovations in temperature monitoring and energy-efficient equipment are driving demand.

Types of Vaccine Storage Equipment

1. Vaccine Refrigerators

Maintain temperatures between 2°C and 8°C.

Commonly used for vaccines such as DTP, polio, and MMR.

Advanced models come with temperature monitoring systems to ensure stability.

2. Vaccine Freezers

Used for storing vaccines requiring sub-zero temperatures, such as certain COVID-19 vaccines.

Ultra-low-temperature freezers can reach temperatures as low as -80°C.

3. Cold Boxes and Vaccine Carriers

Portable solutions used in last-mile delivery of vaccines.

Ideal for remote areas with limited access to electricity.

4. Temperature Monitoring Devices

Real-time monitoring systems track and log temperature data.

IoT-based solutions provide alerts in case of deviations.

Key Market Trends

Post-Pandemic Recovery and Resilience

The COVID-19 pandemic highlighted the importance of vaccine storage solutions, leading to significant investments in cold chain infrastructure. Companies are now focusing on ensuring long-term resilience to future pandemics.

Adoption of IoT and AI in Vaccine Storage

The integration of IoT devices and AI-powered analytics is revolutionizing vaccine storage. Smart refrigerators equipped with sensors can automatically adjust temperatures and send alerts in case of system failures.

Sustainability Initiatives

Energy-efficient vaccine storage equipment is gaining popularity as healthcare providers aim to reduce carbon footprints. Solar-powered refrigerators are a promising solution for off-grid locations.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=52873073

Focus on Remote and Rural Areas

Global immunization efforts are prioritizing underserved regions. Lightweight, portable vaccine carriers are enabling vaccine delivery to remote areas.

Growth Drivers

Several factors are fueling the growth of the vaccine storage equipment market:

Global Immunization Programs

Initiatives by organizations like WHO, UNICEF, and GAVI are significantly increasing demand for vaccine storage solutions. These programs aim to eliminate vaccine-preventable diseases, especially in low-income countries.

Rising Prevalence of Infectious Diseases

With the emergence of new diseases like COVID-19, RSV, and variants of influenza, vaccine production and storage needs have surged.

Government Support and Funding

Governments worldwide are investing heavily in cold chain infrastructure, providing subsidies and grants for healthcare facilities to procure vaccine storage equipment.

Expansion of Biopharmaceuticals

The growing pipeline of vaccines for various diseases, including cancer and genetic disorders, is driving demand for advanced storage solutions.

Challenges in the Vaccine Storage Equipment Market

High Costs

Advanced storage equipment, particularly ultra-low-temperature freezers, can be prohibitively expensive for smaller healthcare providers and developing nations.

Infrastructure Gaps in Developing Countries

Inadequate cold chain infrastructure, lack of reliable electricity, and logistical challenges hinder vaccine storage and distribution in some regions.

Stringent Regulatory Requirements

Vaccine storage equipment must comply with strict regulations to ensure reliability. Meeting these standards can be a challenge for manufacturers.

Temperature Excursions

Even brief deviations from required temperature ranges can compromise vaccine efficacy, underscoring the need for robust temperature monitoring systems.

Regional Insights

1. North America

The largest market for vaccine storage equipment due to high healthcare spending and strong infrastructure.

Widespread adoption of advanced technologies like IoT and AI-based monitoring systems.

2. Europe

Significant investments in cold chain systems driven by government initiatives and pharmaceutical R&D.

Countries like Germany, France, and the UK lead in technological adoption.

3. Asia-Pacific

Rapidly growing market due to large population sizes and increasing immunization campaigns.

Governments in countries like India and China are upgrading cold chain infrastructure to meet rising vaccine demands.

4. Africa and Latin America

Growing focus on expanding vaccine coverage in underserved areas.

International organizations play a critical role in funding and infrastructure development.

Major Players in the Vaccine Storage Equipment Market

Key companies operating in the vaccine storage equipment market include:

Thermo Fisher Scientific

Panasonic Healthcare

Haier Biomedical

Helmer Scientific

B Medical Systems

Vestfrost Solutions

These companies are investing in R&D to develop innovative and energy-efficient vaccine storage solutions.

Future Opportunities

Rising Demand for Personalized Vaccines

The development of personalized vaccines for cancer and rare diseases will drive the need for advanced storage solutions tailored to unique temperature requirements.

Cold Chain Automation

Automation in cold chain logistics, including robotic handling and AI-driven systems, will enhance vaccine storage and distribution efficiency.

Partnerships and Collaborations

Governments, non-profits, and private companies are forming partnerships to improve vaccine accessibility in low-income regions.

Emerging Markets

Expanding healthcare infrastructure in emerging economies presents untapped opportunities for vaccine storage equipment manufacturers.

Conclusion

The vaccine storage equipment market is poised for significant growth in the coming years, fueled by advancements in technology, increasing vaccine production, and global immunization efforts. However, addressing challenges such as high costs and infrastructure gaps will be crucial for ensuring equitable access to vaccines worldwide.

As the world continues to prioritize healthcare innovation, the demand for reliable, efficient, and sustainable vaccine storage equipment will only increase, making this an exciting and vital industry to watch.

[wellnesstribe]

Travel Vaccines Market Drivers: Analyzing the Surge in Tourism and Emerging Infectious Diseases Impact

The travel vaccines market has witnessed significant growth in recent years, driven by various factors ranging from an increase in international tourism to heightened awareness of infectious diseases. Travel vaccines are essential for travelers heading to regions with endemic diseases, helping prevent outbreaks and protecting global health. This blog delves into the primary drivers propelling the growth of the travel vaccines market.

1. Increase in Global Travel and Tourism A key driver of the travel vaccines market is the rapid growth of international travel and tourism. According to the United Nations World Tourism Organization (UNWTO), the number of international tourist arrivals has consistently risen over the years, contributing to the increased demand for vaccines. Travelers to countries with high incidences of diseases such as malaria, yellow fever, and typhoid require specific immunizations to safeguard their health. With more people traveling to regions with endemic diseases, the need for travel vaccines has surged, significantly influencing market growth.

2. Growing Awareness About Health Risks While Traveling As people become more health-conscious, they are increasingly aware of the risks posed by infectious diseases during their travels. The advent of global health crises, such as the COVID-19 pandemic, has highlighted the importance of staying protected through vaccination. The rising awareness about preventable diseases such as Hepatitis A, Hepatitis B, and Japanese Encephalitis has encouraged travelers to seek vaccinations before embarking on their journeys. Health organizations, travel agencies, and government bodies are emphasizing the importance of pre-travel vaccination, contributing to the expansion of the market.

3. Government Initiatives and Regulations Governments and health authorities around the world play a significant role in promoting the travel vaccines market. Many countries require certain vaccinations for travelers before they can enter, particularly for those visiting regions with a high risk of specific diseases. The World Health Organization (WHO) also provides recommendations on vaccinations for travelers, ensuring that individuals are well-protected. In addition, international travel health certifications, such as the Yellow Fever vaccination certificate, are mandatory for entry into certain countries, further boosting the demand for vaccines.

4. Advancements in Vaccine Development and Distribution Advancements in vaccine technology have also contributed to the market’s growth. The development of new vaccines that target diseases specific to travelers has made it easier for individuals to protect themselves from infections. Furthermore, improvements in vaccine distribution and storage, such as the introduction of easier-to-handle vaccines that do not require strict refrigeration, have made it more convenient for people to get vaccinated. As vaccines become more accessible, travelers are more likely to prioritize their health and get vaccinated before traveling.

5. Rising Incidence of Emerging Infectious Diseases The increasing prevalence of emerging infectious diseases, such as Zika virus, Ebola, and COVID-19, has spurred the demand for travel vaccines. In particular, global health emergencies have led to more stringent requirements for travelers, making it essential to stay vaccinated. With diseases spreading rapidly across borders, travelers are now more vigilant about their health and are turning to vaccines as a preventive measure. The awareness of such diseases and their potential risks has significantly increased the need for vaccines, accelerating market growth.

Conclusion In conclusion, the travel vaccines market is driven by a combination of factors, including the surge in global travel, heightened awareness of health risks, government regulations, advancements in vaccine technology, and the rising threat of emerging infectious diseases. As the world becomes more interconnected, the demand for travel vaccines will continue to rise, ensuring that travelers remain safe and protected against preventable diseases. The travel vaccines market, which has become an integral part of global public health, is poised for sustained growth in the coming years.

[the-latest-research]

Vaccines Market Estimated to be Worth $71.50 Billion in 2031

Meticulous Research®– a leading global market research company, published a research report titled ‘Vaccines Market Size, Share, Forecast, & Trends Analysis by Indication (Pneumococcal, Influenza, HPV, DTP, MMR, Hepatitis, COVID-19) Administration (IM, SC, Oral) Type (Inactivated, Combination) Valence (Multivalent, Monovalent) - Global Forecast to 2031.’

According to this latest publication from Meticulous Research®, the vaccines market is projected to reach $71.50 billion by 2031, at a CAGR of 2.3% during the forecast period. This market's growth is driven by a strong pipeline for vaccines, increasing government initiatives toward immunization, and technological advancements in the vaccine industry. Moreover, the rising prevalence of diseases, growing focus on therapeutic vaccines, and growth prospects in emerging markets are expected to offer growth opportunities for the players operating in this market.

However, the high costs involved in vaccine development and the long timelines of vaccine manufacturing restrain the market’s growth. Additionally, product recalls and inadequate access to vaccines pose challenges to the market’s growth.

Download Sample Report Here @ https://www.meticulousresearch.com/download-sample-report/cp_id=5076

Key Players

The key players operating in the vaccines market are Sanofi (France), Merck & Co., Inc. (U.S.), GlaxoSmithKline plc (U.K.), Pfizer Inc. (U.S.), Johnson & Johnson (U.S.), Daiichi Sankyo Co., Ltd. (Japan), Takeda Pharmaceutical Company Limited (Japan), CSL Limited (Australia), Emergent BioSolutions Inc. (U.S.), and AstraZeneca PLC (U.K.).

Vaccines Market: Future Outlook

The vaccines market is segmented based on Indication (Pneumococcal Disease, Influenza, Human Papillomavirus (HPV), Diphtheria, Tetanus, and Pertussis (DTP), Meningococcal Disease, Measles, Mumps, and Rubella (MMR), Rotavirus, Poliomyelitis (Polio), Hepatitis, COVID-19, Other Indications), Route of Administration (Intramuscular, Subcutaneous, Oral, Other Route of Administration), Type (Subunit & Conjugate Vaccines, Inactivated Vaccines, Live-Attenuated Vaccines, Toxoid Vaccines, Combination Vaccines), and Valence (Multivalent and Monovalent Vaccines) and Geography. The study also evaluates industry competitors and analyzes their market share at global and regional levels.

Based on indication, the vaccines market is segmented into pneumococcal disease, influenza, human papillomavirus (HPV), diphtheria, tetanus, pertussis (DTP), meningococcal disease, measles, mumps, rubella (MMR), rotavirus, poliomyelitis (polio), hepatitis, COVID-19, and other indications. In 2024, the pneumococcal disease segment is expected to account for the largest share of the vaccines market. The large market share of this segment can be attributed to the rising incidence of pneumococcal diseases such as pneumonia, meningitis, febrile bacteremia, otitis media, and sinusitis; and the development of quality vaccines such as PPSV23.

Based on route of administration, the vaccines market is segmented into intramuscular (IM), subcutaneous (SC), oral, and other routes of administration. In 2024, the intramuscular (IM) segment is expected to account for the largest share of the vaccines market. The large market share of this segment can be attributed to the ease of intramuscular administration and quick absorption of vaccines administered through the intramuscular route. Further, due to the COVID-19 pandemic, there has been increased adoption of the intramuscular route of administration, as many COVID-19 vaccines are being administered through this route.

Based on type, the vaccines market is segmented into subunit & conjugate vaccines, inactivated vaccines, live-attenuated vaccines, toxoid vaccines, and combination vaccines. In 2024, the subunit & conjugate vaccines segment is expected to account for the largest share of the vaccines market. The large market share of this segment can be attributed to the subunit & conjugate vaccines’ long-term immunity, high safety, and stability compared to vaccines with other antigens.

Based on valence, the vaccines market is segmented into multivalent vaccines and monovalent vaccines. In 2024, the multivalent vaccines segment is expected to account for the larger share of the vaccines market. The large market share of this segment can be attributed to the launch of newer multivalent vaccines, increasing investments by key players in the R&D of multivalent vaccines, and technological advancements in the production of multivalent vaccines.

Geographic Review

This research report analyzes major geographies and provides comprehensive analysis for North America (U.S and Canada), Europe (Germany, France, U.K., Italy, Spain, Switzerland, Netherlands, and Rest of Europe), Asia-Pacific (China, Japan, India, Australia, South Korea, and Rest of Asia-Pacific), Latin America (Brazil, Mexico, Rest of Latin America) and Middle East & Africa. In 2024, North America is estimated to account for the largest share of 41.2% of the vaccines market, followed by Europe and Asia-Pacific. North America’s major market share is attributed to the growing research & development, product launches, and the establishment of new facilities in the region by key players.

Complete Report Here : https://www.meticulousresearch.com/product/vaccines-market-5076

Key Questions Answered in the Report:

Which high-growth market segments are in terms of indication, route of administration, type, valence, and regions/countries?

What was the historical market for vaccines across the globe?

What are the market forecasts and estimates for the period 2024-2031?

What are the major drivers, restraints, challenges, and opportunities in the vaccines market?

What is the competitive landscape like, and who are the market leaders in the vaccines market?

What are the recent developments in the vaccines market?

What strategies are adopted by the major players in the vaccines market?

What are the geographical trends and high-growth regions/countries?

Contact Us: Meticulous Research® Email- sales@meticulousresearch.com Contact Sales- +1-646-781-8004 Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous-research

[global-research-report]

Global Strategies for Meningitis Prevention: Trends in the Meningococcal Vaccine Market

The global meningococcal vaccines market size is expected to reach USD 5.28 billion by 2030, registering a CAGR of 6.0% over the forecast period, according to a new report by Grand View Research, Inc. Increasing prevalence of meningitis is one of the major factors attributed to the market growth. For instance, according to ECDC, it was estimated that in 2017, 3,221 confirmed cases were observed in EU member states, wherein 58% cases were found in the U.K., France, Spain, and Germany. Moreover, a high incidence of meningitis disease is found in the “meningitis belt” of sub-Saharan Africa, and approximately 30,000 cases are reported every year in this region.

In addition, rising FDA approval for meningococcal vaccines is expected to boost the growth. For instance, in April 2020, Sanofi received FDA approval for its MenQuadfi Meningococcal Conjugate Vaccine for the prevention of invasive meningococcal disorders in individuals at least two years old. The increase in approval of novel vaccines is expected to improve meningococcal prevention which in turn, is anticipated to drive the market. 

Initiatives undertaken by the government to combat the rising incidence of the disease are anticipated to boost the meningococcal vaccine market growth. For instance, from April 2019, Nimenrix was made available for free as a part of the National Immunization Program (NIP) in Australia for the age group 15 to 19 years. Nimenrix is a quadrivalent meningococcal vaccine that targets serogroups A, C, W & Y. 

According to WHO, as of 2021, 24 of the 26 nations in the meningitis belt have introduced mass preventive campaigns targeting the age of 1 to 29 years. Moreover, around 13 nations have undertaken the vaccine in their national routine immunization programs. Such initiatives undertaken by countries having high disease burdens are expected to boost the market growth. 

Non-profit organizations entering into strategic initiatives such as partnering, alliances, and others to improve access to new vaccines for vulnerable children are anticipated to drive the market. For instance, in September 2021, WHO and its partners announced the first-ever global strategy to defeat meningitis. This initiative aims to reduce epidemics of bacterial meningitis. Under this strategy, WHO goals to save more than 200,000 lives annually. 

The availability of vaccines at lower prices in countries with an increasing prevalence of the meningococcal disease is anticipated to fuel the revenue of the manufacturers and drive the meningococcal vaccine market. For instance, under Meningitis Vaccine Project, MenAfriVac costs less than USD 0.5 per dose. 

Meningococcal Vaccines Market Report Highlights

Quadrivalent vaccines dominated for the largest revenue share of 51.1% in 2022 in type segment owing to their ability to target four serogroups and the strong presence of vaccines such as Menveo, Menactra, and Nimenrix

The infants (0-2 years) segment is expected to be the fastest-growing segment over the forecast period. The increasing prevalence of meningitis in the age group 9 months to 11 years contributed to the segment growth

Asia Pacific region is expected to witness the highest CAGR over the forecast period. High unmet needs, rising healthcare expenditure, and a large population base in this region are likely to bolster the market

Meningococcal Vaccines Market Segmentation

Grand View Research has segmented the global meningococcal vaccines market on the basis of type, brand, serotype, age group, sales channel, and region:

Meningococcal Vaccines Type Outlook (Revenue, USD Million, 2018 - 2030)

Bivalent

Quadrivalent

Others

Meningococcal Vaccines Brand Outlook (Revenue, USD Million, 2018 - 2030) (Volume, Number of Doses (In Thousands))

Menactra

Menveo

Nimenrix

Trumenba

Bexsero

Others

Meningococcal Vaccines Age Group Outlook (Revenue, USD Million, 2018 - 2030)

Infants (0 to 2 years)

Children And Adults (2 years & above)

Meningococcal Vaccines Serotype Outlook (Revenue, USD Million, 2018 - 2030) (Volume, Number of Doses (In Thousands))

Serotype A

Serotype B

Serotype C

Serotype W-135

Serotype Y

Meningococcal Vaccines Sales Channel Outlook (Revenue, USD Million, 2018 - 2030)

Private

Public

Meningococcal Vaccines Regional Outlook (Revenue, USD Million, 2018 - 2030)

North America

US

Canada

Europe

Germany

UK.

France

Italy

Spain

Russia

Belarus

Georgia

Moldova

Denmark

Sweden

Norway

Asia Pacific

Japan

China

India

Australia

Singapore

South Korea

Thailand

Vietnam

Malaysia

Indonesia

Kazakhstan

Kyrgyzstan

Armenia

Azerbaijan

Tajikistan

Turkmenistan

Uzbekistan

Latin America

Brazil

Mexico

Argentina

Chile

Cuba

Ecuador

Peru

Colombia

Venezuela

Middle East & Africa

Saudi Arabia

South Africa

UAE

Algeria

Egypt

Tunisia

Iran

Turkey

Iraq

Morocco

Kuwait

List of Key Players in Meningococcal Vaccines Market

Pfizer Inc.

Sanofi

Serum Institute of India Ltd.

GlaxoSmithKline plc.

Merck & co., Inc.

Walvax Biotechnology Co., Ltd.

Order a free sample PDF of the Meningococcal Vaccines Market Intelligence Study, published by Grand View Research.